CDK4 and neoplasm: In HER2-driven or oncogenic HRAS-driven breast cancer in mice, tumor development was specifically protected by depleting cyclin D1 or CDK4 or expressing the CDK4- or CDK6-specific inhibitor INK4A or a dominant-negative mutant form of K112E cyclin D1 [46–50].